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In recent decades, the world has undergone a demographic transformation with a rapid growth of 
the elderly population, resulting in an increased demand for funds to maintain their health and drug 
consumption. Pharmacokinetic and pharmacodynamic changes occurring in the elderly can interfere 
directly in the adverse effects of drugs and increase the risk of intoxication. In addition, there are external 
factors interfering with the pharmacotherapy of the elderly, such as inappropriate use and the lack of 
access to information. Many therapeutic classes of drugs should be used with caution or avoided in the 
elderly population, such as anti-inflammatory and some anti-hypertensive drugs, diuretics and digitalis. 
If not managed carefully, these medicines can affect the safety and quality of life in the elderly. Thus, 
the aim of this review was to identify drugs that should be used with caution in elderly patients in order 
to avoid intoxication and/or adverse drug events.
Uniterms: Elderly/inappropriate medicines. Medicines/consumption. Medicines/adverse reaction. 
Medicines/intoxication. Medicine/rational use. Medicine/inappropriate prescribing.
Durante as últimas décadas, o mundo passou por uma transformação demográfica, com um rápido 
crescimento da população idosa e, portanto, tanto a demanda para a manutenção da saúde deste 
grupo populacional, quanto o consumo de medicamentos estão aumentando. Ainda, as mudanças 
farmacocinéticas e farmacodinâmicas que ocorrem em idosos podem interferir diretamente nos efeitos 
adversos dos medicamentos e aumentar o risco de intoxicação. Além disso, há fatores externos que 
interferem na farmacoterapia dos idosos, tais como o uso inadequado e a falta de acesso à informação. 
Existem várias classes terapêuticas de medicamentos que devem ser utilizados com cautela ou evitados 
na população idosa, tais como antiinflamatórios, alguns anti-hipertensivos, diuréticos, digitálicos entre 
outros. Estes medicamentos, se não forem utilizados com cuidado, podem afetar a qualidade de vida e a 
segurança desta população. Assim, este trabalho visa identificar medicamentos que devem ser utilizados 
com cuidado em pacientes idosos para evitar intoxicações e/ou eventos adversos aos medicamentos.
Unitermos: Idosos/medicamentos inadequados. Medicamentos/consumo. Medicamentos/reação adversa. 
Intoxicação medicamentosa. Medicamentos/uso racional. Prescrição inapropriada.
INTRODUCTION
The elderly
Despite the fact that drug consumption is an impor-
tant issue in all age groups, this subject has been more 
extensively studied amongst aged individuals, largely due 
to the structural and functional changes associated with 
the aging process (Nóbrega, Melo, Karnikowski, 2005). 
Generally, adverse drug reactions are observed 2 to 3 times 
more frequently in geriatric patients than in younger adults 
(Turnheim, 1998). This review deals with the principles 
of drug use in the elderly, and the age-related alterations 
in their pharmacokinetics and pharmacodynamics, as con-
sequences of age-related changes occurring in the body’s 
physiological functions.
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The percentage of the elderly population is increasing 
throughout the world as a result of an increased average 
lifespan, and due to this, the National Institute on Aging 
and the National Institute of Health, have redefined the term 
‘‘elderly” as referring to the age group greater than or equal 
to 65 years old (Parker et al., 1997). However, in 1984 the 
World Health Organization defined the concept of elderly in 
a slightly different way, in a report from the Expert Group 
on Epidemiology and Aging. From a chronological point of 
view, the elderly group encompasses the population aged 60 
years or older in developing countries, while in developed 
countries they have maintained the age of 65 years or older 
for the definition of elderly (WHO, 1984).
Elderly patients are characterized by age-specific 
problems such as multi-organ functional decline, alte-
rations in mental status, depression, reduced nutritional 
status and the absence of social support, all of which 
have the potential to interfere with the pharmacotherapy 
of these patients. The biological age of the patient is one 
of the most important parameters and should be defined 
individually, based on co-morbidities and performance 
status (Balducci, Beghe, 2001).
Several factors contribute to the great number of 
adverse drug reactions that affect the elderly besides their 
high drug consumption (Castleden, Pickles, 1988). For 
example, they are more likely to suffer from chronic ill-
ness, so long-term use of medicine may increase the risk 
of adverse drug reactions (Ritz, Vellas, 2007). In addition, 
multiple health problems and polypharmacy (multiple 
drug usage) are common amongst the elderly population, 
which increases the probability of confusion during drug 
administration and the risk of interactions (Turnheim, 
2004; Posner, 2009). 
Another factor that leads to drug toxicity and 
Adverse Drug Reactions (ADRs) in elderly people is 
inappropriate administration of the medication. The stu-
dy conducted by Aparasu and Mort (2004) found a high 
prevalence of elderly persons in the United States that re-
ceived potentially inappropriate psychotropic medications. 
Moreover, Correr et al. (2007) evaluated the prescriptions 
and risks of drug-related problems in a geriatric institution, 
and found that 13.5% of the drugs used were considered 
inadequate, increasing the risk of problems with drugs, 
mainly concerning the safety of the therapy. Moreover, 
these authors identified 69 drug interactions in 38 patients 
(51.3%), with events especially related to therapeutic 
effectiveness (Correr et al., 2007).
There are established criteria to determine inap-
propriate drugs for elderly usage, the most widely used 
being Beers’s Criteria. These criteria, prepared by experts 
in the United States of America, contain an explicit list 
of 48 medicines or classes of drugs that should not be 
used in elderly patients, independent of the pathological 
condition, such as muscle relaxants and antispasmodics, 
some antidepressants, long-acting benzodiazepines, short-
acting dipyridamole, methyldopa, clonidine, cimetidione 
and mineral oil, plus a list of 20 inappropriate drugs with 
specific pathological conditions, for example α-Blockers 
for elderly patients with stress incontinence and calcium 
channel blockers for elderly patient with chronic consti-
pation (Fick et al., 2003).
Another screening tool cited for use in identifying 
the potentially inappropriate prescribing of drugs for older 
people is the “Improving Prescribing in The Elderly” tool 
(IPET). This is a Canadian guideline including 14 ins-
tances of inappropriate prescribing and is a combination 
of explicit contraindications, and adverse drug–drug and 
adverse drug–disease interactions (Naugler et al., 2000). 
However, the guideline has not been as widely used as 
Beers criteria in published research studies.
Nevertheless, no explicit criteria covers all drugs 
that should be avoided or used with caution in this group 
of patients, but it is necessary to consider the implicit 
information about medications, and take into account the 
needs and circumstances of each patient in order to avoid 
ADRs and/or intoxication.
METHOD
The search for articles was carried out on the Pub-
Med, Science Direct and Scielo databases. This survey 
was concerned with appropriate and inappropriate drugs 
for the elderly and/or compromise in the quality of life 
and safety of this patient group. The keywords used were 
“elderly”, “drugs”, “inappropriate prescribing”, “adverse 
drug reaction” and “intoxication”, and the articles included 
were in the English and Portuguese languages. After the 
search for articles, an analysis was carried out to select 
relevant articles from the title and abstract, with no limit 
on the date of publication of the articles.
Pharmacokinetics in the elderly
Age-related changes in the pharmacokinetics and 
pharmacodynamics of patients may cause an increase in 
ADRs in elderly people. In fact, aging causes a number of 
changes in drug absorption, distribution, biotransforma-
tion, and elimination (Galeotta et al., 1990). 
The most important factors influencing drug ab-
sorption in the aged are: the rise in gastric pH because 
of a reduction in acid output due to a decrease in gastric 
parietal cells (Greenblatt, Sellers, Shader, 1982). This rise 
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in gastric pH increases the absorption of basic drugs and 
reduces absorption of acid drugs, for example, antidepres-
sants that are weakly basic are quickly absorbed in the 
intestine, which is weakly acid; the reduction in gastroin-
testinal motility, consequently delaying gastric emptying 
(Galeotta et al., 1990); the reduction in splanchnic blood 
flow due to diminished cardiac output (Safar, 1990); and 
the decrease in absorption surface (Gareri et al., 1998).
On the other hand, most drug absorption from the 
gastrointestinal tract is by passive diffusion and there is 
little evidence to suggest that there are significant age-
related changes in the amount of drug absorption, with one 
exception, levodope. The amount of levodope absorbed 
increases in the elderly because the dopa-decarboxylase le-
vels in the gastric mucosa diminish with age, and therefore 
less levodopa is degraded in the stomach (Noble, 2003). 
Some substances (such as iron and calcium) that enter the 
bloodstream by active transport mechanisms are poorly 
absorbed in the elderly, where this effect can alter transport 
protein activity, and have other consequences that reshape 
drug absorption profiles among older patients (Turnheim, 
2003). However, important changes are seen in the elderly 
when it comes to drug-drug interactions. For instance, 
antacids decrease the oral absorption of H2-antagonists 
(e.g., cimetidine and ranitidine), and alcohol accelerates 
the absorption of chloral hydrate (Noble, 2003).
The distribution of a drug is influenced by tissue 
blood flow, plasma protein binding and the physicoche-
mical properties of the drug itself (Galeotta et al., 1990). 
Moreover, it is influenced by lean and non-lean body mass, 
total body water and extracellular volume (Kyle et al., 
2001). Since adipose mass increases with aging, while to-
tal body water is reduced, the distribution volume is lower 
for water-soluble drugs and greater for lipid-soluble ones, 
such as verapamil, diazepam, nitrazepam, amytriptiline 
and amiodarone (Turnheim, 2003). Therefore these drugs 
tend to accumulate in the adipose tissue, and consequently 
their plasma half-life and their actions increase, thus cau-
sing the risk of adverse effects in the elderly (Greenblatt, 
Sellers, Shader, 1982; Furlanut, Benetello, 1990).
The body distribution of medications can be affected 
by changes in body composition and changes in protein 
binding. As stated above, the elderly usually have an in-
crease in adipose tissue, decrease in lean body mass and 
reduction in total body water (Gareri et al., 1998). These 
alterations can cause significant changes in the volume 
distribution of various medications. For water-soluble 
drugs, the reduced volume distribution can increase the 
initial concentration in the central compartment, causing 
higher plasma concentrations, as in the case of cimetidine, 
digoxin, gentamicin and theophylline (Noble, 2003).
The elderly also tend to have decreased albumin 
and increased alpha1 acid glycoprotein levels, which 
can make the elderly more susceptible to acute effects of 
multiple drug therapy when highly protein-bound drugs 
are prescribed together. As the body ages, cardiac output is 
often reduced and peripheral vascular resistance increases, 
leading to a decrease in total systemic perfusion of the vital 
organs, including the kidneys and liver. This reduction in 
perfusion can decrease the body’s ability to metabolize 
and excrete drugs (Cooney, Pascuzzi, 2009).
Changes in drug metabolism can elevate drug res-
ponses in elderly patients. There is a decrease in hepatic 
blood flow compared to a 25 year-old, resulting in a major 
reduction in the first-pass metabolism of the drugs. Me-
dications subject to oxidative phase I metabolism exhibit 
decreased elimination, because phase I metabolism is 
catalyzed by the cytochrome P450 (CYP 450) system in 
the smooth endoplasmic reticulum of the hepatocytes, 
a process that diminishes with age (Cooney, Pascuzzi, 
2009). Some antihypertensive medicines that are affected 
by this first-pass metabolism include propranolol, verapa-
mil and nifedipine (Tanaka, 1998). Phase II metabolism, 
which involves the conjugation of a drug molecule by 
glucuronidation, acetylation or sulfation, is not generally 
affected by age. For example, if an antihypertensive drug 
listed above is prescribed to an elderly patient and taken 
together with a potent CYP 3A4 inhibitor, a potentially 
serious drug interaction can occur, leading to toxicity 
(O’Mahony, Woodhouse, 1994; Noble, 2003; Cooney, 
Pascuzzi, 2009).
Renal function progressively declines with advan-
cing age. A reduction in renal plasma flow, renal tubular 
clearance and creatinine clearance, and an increase in 
serum creatinine occur in the elderly, due to their decline 
in muscle mass. Altered renal clearance leads to two clini-
cally significant effects: prolonged half-lives of drugs; and 
an increase in their serum levels (Noble, 2003; Cooney, 
Pascuzzi, 2009). For drugs with a narrow therapeutic index 
(e.g. digoxin, cimetidine, aminoglycosides, warfarin), se-
rious side effects may occur in older patients if appropriate 
dose reductions are not applied (Noble, 2003).
Pharmacodynamics in the elderly
In a review carried out by Williams and Lowenthal 
(1992), many changes in the pharmacodynamics of drugs 
in elderly patients were evidenced, due to alterations in the 
interactions between the drugs and receptors. Some drugs 
should be given with extreme caution to the elderly, for 
example warfarin, since it causes greater risk of hemorrha-
ge in these patients, and they are also more sensitive to the 
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effects of potent analgesics and benzodiazepines. On the 
other hand, the elderly are less sensitive to some of the car-
diovascular effects of isoproterenol and propranolol. The 
alpha-adrenergic receptors have shown either no change 
or a decrease in the number and affinity of these receptors 
with age (Williams, Lowenthal, 1992).
Pharmacotherapy in elderly patients
The relationship between ageing and the organism’s 
response to drugs has been further explored, studying the 
effects of the different classes of drugs in both old and 
young subjects. 
Central nervous system drugs
The elderly are more sensitive to medications that 
affect the central nervous system function (Williams, Lo-
wenthal, 1992). An overview of these is described further 
below.
Benzodiazepines
Psychopharmacological treatment is an integral part 
of the treatment for anxiety disorders. Benzodiazepines 
are the most commonly used psychotropic drugs amongst 
older people (Uchida, Mamo, 2009) and are widely used 
in older patients with anxiety disorders (Kirby et al., 1999; 
Uchida et al., 2009).
The adverse effects of benzodiazepine include dizzi-
ness, ataxia, drowsiness, and impairment of psychomotor 
function, and these effects appear to increase with age. The 
greater sedation and degree of psychomotor impairment in 
the elderly may be due to reduced clearance of the drug, 
and since it is lipid-soluble, also due to higher plasma 
concentrations (Greenblatt et al., 1991). Benzodiazepines 
with long-duration action (e.g. diazepam) are particularly 
likely to accumulate and therefore have a greater potential 
for sedative effects and psychomotor impairment (Kirby et 
al., 1999). Older people who are taking benzodiazepines 
with a long elimination half-life have been shown to have 
an increased risk of falls (Tinetti, Speechley, Ginter, 1988), 
a greater risk of hip fracture (Ray, Gri, Downey, 1989) and 
an increased chance of being involved in a motor vehicle 
crash (Hemmelgarn, Suissa, Huang, 1997).
Simon et al. (1996) reported that in 1992, the use 
of benzodiazepine increased with patient age among the 
members of a large United States health maintenance orga-
nization. Other studies carried out between 1989 and 1997 
in a variety of Western countries reported that 10%–17% 
of elderly community residents used benzodiazepines 
(Kirb et al., 1999; Blazer et al., 2000). Moreover, Tu and 
colleagues (2001) reported that in 1993, about 25% of 
elderly individuals in the Canadian province of Ontario 
used benzodiazepines, whereas in 1998, approximately 
23% used these medications. Thus the use of benzodiaze-
pine, although declining, remained substantial amongst 
elderly Canadians. 
It is known that the risks arise from the long-term 
use of benzodiazepine, and long-term users can develop 
withdrawal symptoms if benzodiazepines are discontinued 
abruptly (Schweizer, Rickels, 1998). Cognitive impair-
ments indisputably occur with the acute administration 
of benzodiazepines, but the studies differ over the extent 
of cognitive impairments amongst long-term users. Some 
studies state continued cognitive difficulties with chronic 
use (Hanlon et al., 1998), whereas others report only 
modest impairments amongst healthy long-term users 
(McAndrews et al., 2003). Some evidence also suggests 
that chronic benzodiazepine use is linked to subsequent 
development of dementia (Paterniti et al., 2002). 
Benzodiazepines are lipid soluble medications that 
have a prolonged half life in the elderly because of their 
accumulation in lipid tissue. Due to the extended duration 
of action and increased sensitivity to sedative hypnotics 
in the elderly, benzodiazepines can cause delirium (Ala-
giakrishnan, Wiens, 2004). According to Beers’ criteria, 
the long-acting benzodiazepines should be avoided, and 
therefore short and intermediate-acting benzodiazepines 
are preferred in the elderly (Fick et al., 2003).
Antidepressants
Depression is a common disorder in the elderly. 
Estimations of the prevalence of major depressive disor-
der vary from 1% to 3% amongst the elderly (Mulsant, 
Ganguli, 1999). An additional 10% to 25% of the elderly 
show substantial depressive symptoms that do not meet the 
Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM IV) criteria for major depression. 
Depression in the elderly has been associated with dimi-
nished quality of life, increased functional disability, in-
creased use of health care resources, and poorer outcomes 
in patients with a variety of medical disorders (Kotlyar, 
Dysken, Adson, 2005).
It has been well documented in the literature that 
older adults metabolize pharmacological agents slower 
than younger adults, and are at greater risk for developing 
adverse side effects or acute toxic reactions, and are more 
likely to have multiple medical diseases that will need 
extra medications that may complicate the treatment with 
antidepressant medication (Teri et al., 1991). Data pro-
viding clinical recommendations for depressed elderly 
patients is limited, and consequently the treatment recom-
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mendations are usually based on data from younger patient 
populations or from small studies of elderly patients. In 
addition, the medically ill and the “oldest old” (>85 years) 
are generally not included in clinical trials, and thus data 
regarding such patients is even more scarce. Finally, scant 
information is available regarding antidepressant efficacy 
in the most common mood disorders in elderly patients, 
such as dysthymic disorder, minor depression or mixed 
anxiety and depression (DasGupta, 1998).
· Tricyclic Antidepressants (TCAs)
For several decades, tricyclic antidepressants 
(TCAs) were considered the cornerstone of antidepressant 
therapy. Although TCAs are effective antidepressants, 
their adverse effect profile limits their use, for example, 
muscarinic receptor blockade results in several particularly 
troublesome adverse effects for elderly patients, such as 
dry mouth, sweating, tachycardia, urinary retention, blur-
red vision, postural hypotension and confusion. Another 
TCA effect is postural hypotension that may have severe 
consequences, such as sudden drops in blood pressure whi-
ch increase the potential for hip fracture (high incidence 
femoral neck fracture), stroke or myocardial infarction 
(Halaris, 1987; Koenig, 1991; Gareri et al., 1998). A study 
of 1021 patients with hip fractures demonstrated a clear 
relationship between TCA therapy and its risk (DasGupta, 
1998).
In addition, TCAs may cause arrhythmias, heart blo-
cks (Jefferson, 1975) and slow atrioventricular conduction 
(Veith et al., 1982). TCA have important side effects in the 
central nervous system, more specifically, antimuscarinic 
effects such as xerostomy, constipation, paralytic ileus 
and urinary retention. Amitryptiline provokes sedation 
and exhibits strong anticholinergic properties (Fick et al., 
2003). Imipramine shows an antiarrhythmic action and 
nortriptyline causes difficulty in falling sleep. Nortiptiline 
and desipramine appear to be the best tolerated tricyclics in 
older people. However, second generation antidepressants 
are preferred for the elderly and for those patients with 
heart disease, since they have milder side effects and are 
less toxic in terms of overdose (Gareri et al., 1998).
It is important to note that in elderly patients, all 
antidepressants can contribute to delirium. The tricyclic 
antidepressants have an anticholinergic effect and can 
induce delirium. Amongst the selective serotonin uptake 
inhibitors, paroxetine has the greatest affinity for musca-
ranic receptors, similar to nortriptyline (Richelson, 1993). 
Dopaminergic medications such as levodopa or dopamine 
agonists can contribute to delirium in a dose-related man-
ner, and in elderly patients with dementia, lithium can 
cause delirium even at therapeutic serum levels (Brown, 
Rosen, 1992). Meperidine (Demerol®, pethidine) is often 
avoided in seniors due to its accumulation as a result of 
decreased renal function. Meperidine is converted to an 
anticholinergic metabolite that can cross the blood-brain 
barrier and lead to delirium (Alagiakrishnan, Wiens, 
2004).
In patients with Dementia of the Alzheimer’s type 
(DAT), the effects of medication are particularly worriso-
me. The anticholinergic effects of common antidepressants 
such as the TCAs, may serve to increase cognitive deficits 
in non-demented older adults, and patients with DAT alre-
ady demonstrate loss of cholinergic neuronal function, so 
TCAs may exacerbate the cognitive impairment of DAT 
patients (Teri et al., 1991).
The symptoms of depression, apathy and fatigue, are 
common symptoms amongst medically-ill older adults and 
patients with advanced disease, and have been associated 
with morbidity and mortality. Methylphenidate has been 
used to treat these symptoms because of its rapid effect 
(Hardy, 2009). 
· Psychostimulants
Since their introduction in the 1930s, psychostimu-
lants such as amphetamine and methylphenidate have been 
used in the treatment of depression. Methylphenidate is 
a central nervous system stimulant approved by the US 
Food and Drug Administration (FDA) for the treatment 
of attention-deficit/hyperactivity disorder and narcolepsy 
(Sood, Barton, Loprinzi, 2006). Some studies have shown 
an increase in liver enzymes, and blood pressure altera-
tions in older patients treated chronically with this drug 
(Hardy, 2009). Amphetamines and anorexic agents show 
a high potential for causing dependence, hypertension, 
angina and myocardial infarction, particularly in elderly 
patients (Fick et al., 2003).
· Atypical antidepressants
The atypical antidepressants are new molecules 
with the effects of tricyclic ones, only with far fewer side 
effects (Gareri et al., 1998). Of these, trazodone causes 
dizziness, drowsiness and especially orthostatic hypoten-
sion, while there are no antimuscarinic effects apart from 
xerostomy (Haria, Fitton, Mctavish, 1994). Bupropion, an 
aminoketone compound with 3 pharmacologically active 
metabolites, is an effective and well-tolerated antidepres-
sant in elderly patients. Although its mechanism of action 
remains unclear, bupropion may exert its antidepressant 
activity via noradrenergic systems (DasGupta, 1998). The 
principal adverse effects of bupropion include insomnia, 
agitation and headache. Akin to the Selective Serotonin 
Reuptake Inhibitors (SSRIs), bupropion can cause weight 
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loss, which may be a problem in frail, debilitated, elderly 
persons (Small, 1991).
· Selective Serotonin Reuptake Inhibitors (SSRIs)
Fluoxetine is widely prescribed for geriatric patients. 
However, despite extensive scientific literature describ-
ing its efficacy and safety, there is little published data 
describing the pharmacokinetics of this drug in the elderly. 
However, Ferguson and Hill (2006) performed a study of 
the plasma concentration of fluoxetine and norfluoxetine 
in such subjects, and observed a higher concentration than 
previously reported in the literature, due to the longer 
elimination half-life in the elderly. Thus, these high levels 
of fluoxetine in the plasma of elderly patients may lead to 
toxic effects (Ferguson, Hill, 2006), producing excessive 
central nervous system stimulation, sleep disturbances 
and increasing agitation (Fick et al., 2003). The efficacy 
of paroxetine seems to be comparable to other SSRIs in 
the treatment of approved indications, although treatment 
with paroxetine induces more sedation, constipation, 
sexual dysfunction, discontinuation syndrome and weight 
gain than other SSRIs (Marks et al., 2008). Sertraline and 
citalopram are drugs recommended for depressive elderly 
patients, because there are fewer side effects (Gareri et 
al., 1998).
· Monoamine Oxidase Inhibitors (MAOIs)
Although MAOIs are effective agents for major 
depression, for the depressive phase of bipolar disorder 
and for “atypical” depression (i.e., depression with hyper-
somnia and hyperphagia), they are currently not first line 
drugs and are infrequently used in elderly patients (Das-
Gupta, 1998).
Drugs inhibiting mitochondrial monoamine oxida-
se have mild antimuscarinic effects. Nevertheless, they 
may provoke orthostatic hypotension, insomnia, tremors, 
mental tension and especially severe hypertensive crises, 
which could potentially lead to death. This could occur 
following the ingestion of food containing tyramine, 
tryptophan and tyrosine (Gareri et al., 1998).
· Mood stabilizing drugs
Mood stabilizing drugs are widely used to prevent 
the recurrence of depression and for preventing and 
treating bipolar illness. They include lithium, the anti-
convulsants, carbamazepine and valproic acid (Gareri et 
al., 2000).
Lithium
Lithium, which is used in the treatment of bipo-
lar illness and in mania, requires plasma concentration 
monitoring, because it is metabolized and excreted by 
the kidneys, and there is also renal function decline with 
age. Thus, the dosage should be reduced in older persons 
(Hewick et al., 1977).
Moreover, elderly patients who have concomitant 
physical disease and require the administration of a variety 
of medications that could disrupt the water and electrolyte 
balance may present potentially hazardous fluctuations in 
their lithium concentrations (De Angelis, 1990). Moreover, 
lithium can interfere with renal sodium excretion, modify 
thyroid function and cause heart conduction disturbances. 
Therefore careful monitoring of this drug is required. 
Rare side effects are nausea, diarrhea, abdominal pain 
and weakness. The concomitant administration of a thia-
zide diuretic should be avoided, or at least followed by a 
decrease in the lithium dosage, since its excretion may be 
reduced (Gareri et al., 2000).
Carbamazepine
Carbamazepine is an antiepileptic drug, but in 
psychiatry clinics it is used in the treatment of acute 
mania when lithium is unsuccessful or poorly tolerated, 
and can also be used in bipolar manic-depressive patients 
and added to tricyclic antidepressants in all patients with 
therapy-resistant unipolar depression. Carbamazepine 
elimination is dose-dependent and varies greatly with 
age. Its main side effects are nausea, dizziness, ataxia, 
visual disturbances and in rare cases, aplastic anemia. It 
is a potent enzyme inducer, so it may reduce the levels of 
other drugs such as haloperidol, theophylline, warfarin 
and steroids, and for chronic administration, it can even 
induce the enzymes responsible for its own metabolism, 
such as CYP3A4, cytochrome P450 (CYP), the enzyme 
located in the enterocyte and/or the drug transporter pro-
tein that pumps the drug out into the intestinal lumen: the 
multiple resistance protein (MRP2) (Leppik, 1992; Gareri 
et al., 2000; Fagiolino et al., 2006). Due to these factors, 
carbamazepine should be used with caution, especially in 
elderly patients.
· Drug treatment of epilepsy
The majority of older patients require lower doses 
of antiepileptic drugs (AEDs) than younger adults, howe-
ver higher valproic acid (VPA) doses may be required in 
patients taking drugs which induce hepatic microsomal 
enzymes. Once-daily dosing of controlled-release prepa-
rations can help to improve compliance and may render 
some elderly people seizure free (Stephen, 2003). 
It is known that the elderly are generally more 
susceptible to the adverse effects of AEDs than younger 
adults, since dose-dependent and idiosyncratic reactions 
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may be more frequent. The most common side effects of 
VPA are nausea, vomiting, abdominal pain and heartburn. 
To avoid such side effects a slow tapering of the dosage is 
necessary, especially in the elderly. A severe side effect, 
due to its idiosyncratic toxicity, is hepatotoxicity (Gareri 
et al., 2000).
VPA is a long established AED, and its broad spec-
trum of action and dosing schedule are favorable pro-
perties for its use in older people. Total VPA clearance is 
similar in young and elderly subjects. The drug does not 
induce the metabolism of hepatic enzymes, but can act as a 
metabolic inhibitor (Stephen, 2003). In elderly adults with 
partial-onset seizures, gabapentin and lamotrigine have 
shown efficacy and effectiveness as initial monotherapy 
(Glauser et al., 2006).
· Antipsychotic drugs
Antipsychotics are widely used in geriatric 
psychiatric disorders. The first-line recommendation 
for agitated dementia with delusions is an antipsychotic 
drug alone, but they could also be considering adding a 
mood stabilizer. Risperidone was first line followed by 
quetiapine, and olanzapine as high second-line options. 
While for older patients with delusional disorder, an 
antipsychotic was the only treatment recommended. 
For treatment of geriatric psychotic major depression, 
an antipsychotic plus an antidepressant is recommended 
(Alexopoulos et al., 2004).
It is important to know that if a combination of an-
tidepressants and antipsychotics is necessary, it would be 
much more cautious to use selective serotonin reuptake 
inhibitors that are more potent inhibitors of the CYP 450 
enzymes (i.e., fluoxetine and paroxetine), together with 
nefazodone, TCAs and monoamine oxidase inhibitors. 
Extra monitoring is recommended when combining antip-
sychotic drugs with any of the following: lithium, carba-
mazepine, lamotrigine and valproate (except aripiprazole 
and risperidone plus valproate) or with codeine, phenytoin 
or tramadol (Alexopoulos et al., 2004).
Cardiovascular drugs
Antihypertensive drugs
Hypertension is a major risk factor for cardiovas-
cular disease, stroke and renal disease. It is important to 
highlight the high prevalence of hypertension in elderly, 
as it increases markedly with aging, affecting about 65% 
of the population beyond the seventh decade of life (Bor-
zecki et al., 2003).
The pathophysiology of hypertension in the elderly 
is a multifactorial disease (Cooney, Pascuzzi, 2009). Ac-
cording to Guidelines for treatment of hypertension in the 
elderly, this pathology is characterized by an increase in to-
tal peripheral vascular resistance, decreased compliance of 
the large and middle arteries, tendency towards a decrease 
in cardiac output and circulating blood volume, increased 
lability of blood pressure due to age-related baroreceptor 
function, decreased blood flow and dysfunction of the 
auto-regulation in important target-organs such as the 
brain, heart and kidney. These changes can make treating 
hypertension in the elderly challenging, putting patients at 
increased risk of developing adverse events and compli-
cations with antihypertensive medications. Therefore, it is 
important to treat hypertension in the elderly with special 
attention (Ogihara et al., 2003).
All antihypertensive drugs may predispose older 
patients to the development of symptomatic orthostatic 
hypotension and postprandial hypotension, as well as 
falls and syncope. The adverse effects depend on the 
antihypertensive drugs administered, the doses used, the 
co-morbidities present in the older patients taking these 
drugs, and the drug-drug interactions (Aronow, 2009).
Beta-blockers, especially propanolol, have been 
reported to cause delirium (Alagiakrishnan, Wiens, 2004). 
Calcium antagonists cause many adverse reactions, vera-
pamil causes mainly bradyarrhythmias and obstipation, 
and nifedipine causes mainly hypotension, peripheral 
edema, skin rash, and tachycardia (Pahor et al., 1996).
Diuretics
Diuretic therapy requires extra caution, because 
elderly patients are more susceptible to fluid electrolyte 
disorders, hypokalemia, hyponatremia, hypomagnesemia 
and volume depletion (Williams, Lowenthal, 1992). In 
addition, diuretics can induce delirium by dehydration and 
electrolyte disturbances (Alagiakrishnan, Wiens, 2004).
Age-dependent changes in renal tubular function 
can alter the effect of drugs in the kidney, for instance, the 
effects occurring in the kidney caused by organic acid diu-
retics, such as furosemide and bumetanide. Likewise, the 
tubular renal clearance of bumetanide was lower in older 
healthy outpatients compared to younger volunteers, due 
to reduced renal tubular secretion in the older group. Thus, 
high levels of diuretics in the plasma of elderly people may 
lead to some toxic effects (Cusack, 2004).
Spironolactone alone may not be sufficient to con-
trol blood pressure, especially in older patients. All other 
classes of antihypertensive agents can be used in combi-
nation with this diuretic. If spironolactone is used with the 
angiotensin-converting enzyme inhibitor and angiotensin 
receptor blocker, this increases the risk of hyperkalemia 
(Gaddam et al., 2009).
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Digitalis
In the elderly, because of decreased renal clearance, 
even normal doses of digoxin can accumulate and cause 
toxicity and delirium (Alagiakrishnan, Wiens, 2004), 
therefore the dose should not exceed 0.125 mg/day except 
when treating atrial arrhythmias (Fick et al., 2003). It was 
postulated that the apparent sensitivity of elderly patients 
to digitalis might be related, in part, to the decreased renal 
excretion, because creatinine clearance is decreased in 
the elderly and it is known that digoxin is predominantly 
excreted by the kidneys. Evidence shows that the use of the 
same dose of digoxin in elderly and young adult subjects 
resulted in blood concentrations nearly twice as high in 
the elderly, evidencing the vulnerability of the elderly to 
poisoning by this drug (Ewy et al.,1969).
In another study performed by Dall (1970) involving 
elderly patients on maintenance digoxin doses, about 34%, 
had to stop the treatment because of toxic effects, such 
as arrhythmias, nausea and vomiting, mental confusion, 
refractory cardiac failure, gynaecomastia and xanthopsia.
Statins
Among elderly patients, statins are generally well 
tolerated and adverse events are usually mild and transient. 
Also, the general population’s tolerance to the drugs ro-
suvastatin, atorvastatin, simvastatin and pravastatin was 
similar across treatments (Jones et al., 2003).
The safety of atorvastatin and simvastatin was similar 
in patients aged <65 and >65 years with stable coronary di-
sease. However, when statins are used, the levels of creatine 
kinase (CK), and transaminases (AST and ALT) must be 
monitored, because these drugs can cause rhabdomyolysis 
and myopathy in both elderly and young people (Tikkanen 
et al., 2009). Roberts, Guallar and Rodriguez (2007) found 
musculoskeletal symptoms together with abnormalities in 
CK and liver enzymes to be the most commonly reported 
adverse events in elderly patients.
Deedwania et al. (2007) carried out a comparative 
study between pravastatin and atorvastatin, and observed 
that the serious adverse events were similar with both 
treatments, except for the test for liver function abnorma-
lities, which were more frequent in the atorvastatin group. 
However, the liver enzyme levels returned to normal for 
all patients on repeat testing during the follow-up or after 
discontinuation of the medication. In both studies, no cases 
of rhabdomyolysis were detected (Deedwania et al., 2007), 
but older patients may be more susceptible to the adverse 
effects of these drugs (Tikkanen et al., 2009).
Antiplatelet drugs
Strokes and transient ischemic attacks become 
more common with advancing age and their prognosis 
worsens. Due to the increase in the number of elderly 
subjects in most western societies, atherothrombotic ce-
rebrovascular disease is a significant health problem. It is 
therefore important to find effective treatments for both 
primary and secondary prevention (Sivenius, Riekkinen, 
Laakso, 1995). 
Antiplatelet drugs are administered to the elderly 
in the primary prevention of myocardial infarction, and 
to treat cerebral transient ischemic attacks and ischemic 
strokes. Aspirin has been combined with ticlopidine to 
prevent thrombosis of coronary artery stents. A few stu-
dies have suggested that bleeding complications with anti 
platelet agents may be more severe in the elderly. 
To treatment this disorder there are other anti pla-
telet drugs, such as clopidogrel and abciximab (Green, 
Padrozik, 2000). A study carried out by Bagur et al. 
(2009) compared bleeding and ischemic outcomes after 
transradial percutaneous coronary intervention and ma-
ximal antiplatelet therapy in patients aged <70 or >70 
years old, with acute coronary syndromes. All patients 
received aspirin and clopidogrel before catheterization, 
followed by abciximab at the time of the percutaneous 
coronary intervention. The authors concluded that, under 
the conditions tested, older patients remained more prone 
to gastrointestinal bleeding and local hematoma compared 
to younger patients, and preventive measures need to be 
further investigated (Bagur et al., 2009).
Abciximab, the most potent GPIIb/IIIa inhibitor, 
was also studied by Ndrepepa et al. (2006). These authors 
showed that the efficacy of the drug was age-dependent, 
with no effect in patients >70 years of age, which again 
illustrates the need to carefully evaluate the use of drugs 
in elderly patients.
Oral erectile dysfunction drugs
Sexual function tends to decline with aging, which 
is often associated with a higher prevalence of sexual 
problems, including erectile dysfunction and loss of libi-
do. Particular care was taken to assess the cardiovascular 
safety of oral drugs for erectile dysfunction in this subset 
of patients, who often have multiple cardiovascular risk 
factors which contribute to a clinical complication (Salo-
nia et al., 2005). 
Sildenafil citrate is an orally active inhibitor of 
phosphodiesterase type 5, and it is used as treatment for 
male erectile dysfunction. This drug is cleared almost 
exclusively by hepatic metabolism and its primary meta-
bolite is N-desmethyl metabolite - UK 103,320 (Muirhead 
et al., 2002).
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A study performed by Muirhead et al. (2002) sho-
wed that the pharmacokinetics of sildenafil was affected by 
age. Plasma concentrations of sildenafil and UK 103,320 
rose rapidly in the young and elderly subjects, but in young 
men, the plasma sildenafil concentrations decreased to 
nondetectable concentrations by approximately the 16 h 
post dose, while the concentrations remained detectable 
for up to 36 h in the elderly men. Concentrations of UK 
103,320 were detectable for up to 24 h in the younger 
subjects and 36 h in the elderly subjects. Thus elderly 
patients are more vulnerable to the toxic effects of this 
drug, including headaches, flushing and dyspepsia (Müller 
et al., 2007).
Antidiabetic drugs
Diabetes is an important health condition in the 
aging population. At least 20% of all patients over the 
age of 65 years suffer from diabetes, and this number is 
expected to grow rapidly in the coming decades (Viljoen, 
Sinclair, 2009).
The treatment of diabetes in the elderly may lead to 
serious complications even at relatively low doses. For 
example, the sulphonylureas, especially the long-acting 
agents such as chlorpropamide and glibenclamide, can 
produce life-threatening hypoglycemia. The risk is even 
higher in frail elderly patients with impaired renal function 
(Chan, 2006).
Rosiglitazone also showed an increased risk of 
congestive heart failure, acute myocardial infarction 
and mortality compared with other combined oral hypo-
glycemic agent treatments, while pioglitazone does not 
have these complications. However, both rosiglitazone 
and pioglitazone drugs have been shown to increase bone 
loss in elderly women but not in men (Lipscombe et al., 
2007). In addition, rosiglitazone increased the risk of bone 
fractures in the elderly (Kahn et al., 2006).
Antihistamine drugs
Sedation related to first-generation antihistamine 
use, such as chlorpheniramine, dexchorpheniramine, di-
phenhydramine, hydroxyzine and promethazine, has been 
shown to compromise driving performance and decrease 
the ability to handle tasks that require a high degree of 
alertness or concentration, due to the drowsiness caused 
by these drugs (McCue, 1996).
Second-generation antihistamines are less likely to 
produce sedation. Loratadine, cetirizine and fexofenadine 
are the most commonly prescribed second-generation 
antihistamines. At recommended doses, loratadine is not 
associated with performance impairment, whereas cetiri-
zine at the recommended doses has been shown to impair 
performance and cognition, although to a much lesser 
degree than the older antihistamines. Fexofenadine is non-
sedating even at very high doses, and psychomotor and 
driving tests have reinforced these findings. Loratadine, 
cetrizine, and fexofenadine all have good safety records in 
specific populations, including in elderly patients (Edward, 
Philpot, 2000).
Antibiotics
As mentioned previously, kidney function declines 
with aging, and thus the rate of elimination of drugs excre-
ted mainly by this organ is generally reduced in the elderly. 
Antibiotics form an important group of drugs cleared lar-
gely by the kidney. Aztreonam, meropenem, ceftazidime 
and ofloxacin are examples of antibiotics that need to be 
administered in reduced doses in the elderly, in order to 
avoid toxic effects (Meyers, Wilkinson, 1989).
In addition, the reduced clearance of active metabo-
lites from certain drugs may enhance the therapeutic effect 
but increase the risk of toxicity, particularly in very elderly 
patients with more probable renal impairment. Examples 
include N-acetyl-procainamide, the active metabolite of 
procainamide; morphine-6-glucuronide, the active me-
tabolite of morphine, and normeperidine (norpethidine), 
the metabolite of meperidine (pethidine) (Cusack, 2004). 
In addition, nitrofurantoin (NFT) shows the potential 
for renal impairment in elderly patients (Fick et al., 2003). 
NFT is highly effective against most strains of E. coli and 
the enterococci, but has poor activity against most Proteus, 
Pseudomonas, Enterobacter and Klebsiella spp. The most 
common reactions to NFT are pulmonary (pneumonitis, 
vasculitis, pleuritis) and allergic (cutaneous rashes, fever, 
anaphylaxis) disorders. Pneumonitis is characterized by 
fever, chills, cough, chest pain and dyspnea, and chest 
radiography may reveal infiltrates. Eosinophilia is also 
common, but the symptoms are usually resolved within 
hours of discontinuing the drug. Elderly patients are most 
at risk with respect to this complication and pulmonary 
fibrosis may result from chronic usage (Graeme, Pollack, 
1996). It is important to note that, especially in older wo-
men, treatment with NFT can have several adverse effects, 
including nausea and vomiting and allergic, pulmonary, 
hepatic, neurological and haematological reactions (Nys 
et al., 2006).
In general, the antibiotics prescribed for the treat-
ment of urinary tract infections, specifically those inclu-
ding trimethoprim/sulfamethoxazole, fluoroquinolones, 
nitrofurantoin, amoxicillin, cephalosporins and amino-
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glycosides, are all cleared renally. Consequently, a dosage 
reduction is recommended in patients with reduced renal 
clearance (Takahashi et al., 2004).
Anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAIDs) 
have an increased risk of causing hyperkalemia, renal 
failure and death from gastrointestinal hemorrhage 
(Williams, Lowenthal, 1992). In general, the risk of 
hyperkalemia is increased in patients with chronic kidney 
disease, including the elderly and patients with diabetes 
(Gaddam et al., 2009).
The cyclo-oxygenase (COX)-2 inhibitors are as 
effective as standard NSAIDs for the relief of pain and for 
improving function in elderly patients with osteoarthritis 
and rheumatoid arthritis. Gastroduodenal disorders are 
the most frequently reported serious adverse effects of 
NSAI-s, and occur more frequently in the elderly. Thus, 
COX-2 inhibitors are an alternative to standard NSAIDs 
in this age group but are not appropriate for many pa-
tients with cardiovascular and renal disease. The adverse 
reaction profile of the COX-2 inhibitors confirmed the 
role of the COX-2 enzyme in renal function, salt and 
water homeostasis and the vascular endothelium. Similar 
to standard NSAIDs, COX-2 inhibitors can cause renal 
failure, hypertension and the exacerbation of cardiac fai-
lure, and it should be noted that these disorders are dose 
related. Thus, there are good reasons to avoid high doses 
of COX-2 inhibitors in the elderly. COX-2 inhibitors have 
a thrombotic potential, especially at high doses and when 
their use is prolonged, further limiting the extent to which 
they can be used in the elderly (Savage, 2005). 
Griffin et al. (1991) compared the relative risk of 
peptic ulcers or gastrointestinal hemorrhage in current 
elderly users of five different NSAIDs, and showed a 
significantly greater risk in users of tolmetin, naproxen, 
piroxicam, and meclofenamate than in users of ibuprofen.
Salicylates are the most frequently used over-the-
counter (OTC) drug, and also the most common OTC drug 
contributing to morbidity and mortality (Gittelman, 1993). 
Common in elderly, chronic salicylate intoxication may 
occur even at therapeutic dosages. Older adults are more 
susceptible to salicylism because they frequently take a 
lot of drugs, favoring interactions, and have reduced liver 
and kidney function (which decreases the metabolism and 
excretion of salicylates), and have a variety of generalized 
aches and pains that they self-treat with salicylate-contai-
ning drugs (Courts, 1996).
Toxicity in the elderly can also be high due to inad-
vertent overdosage (Durnas, Cusack, 1992). Salicylate 
toxicity is often overlooked as a cause of confusion in 
elderly patients and tends to go undiagnosed, leading to 
increased morbidity and even death (Courts, 1996).
Chemotherapeutic agents
The increasing number of elderly people in the world 
population has led to a parallel increase in the number 
of older cancer patients (Lonardi, 2007). There is much 
discussion concerning chemotherapy in elderly patients. 
The data on chemotherapy tolerance in older patients is 
conflicting, but there are physiological reasons that support 
the presence of an increased risk of toxicity in the elderly. 
Age-related changes may, in fact, influence the safety of 
cytotoxic agents at three levels: pharmacodynamics, phar-
macokinetics and tolerance of normal tissues (Biganzoli 
et al., 2009).
Complications of chemotherapy such as mucositis, 
anemia, neutropenia, bleeding, cardiac toxicity and neu-
rotoxicity are more frequently observed in the elderly, and 
may affect individual functional independence (Syrigos, 
Karapanagiotou, Harrington, 2005). In addition, chemo-
therapy and most of the agents used to prevent its toxicity, 
interfere with cognition, balance, vision, continence and 
mood. Moreover, polypharmacy may lead to interactions 
with cytotoxic chemotherapeutic agents. All of these 
conditions may increase the risk of chemotherapy in the 
elderly (Syrigos et al., 2009). 
Taxanes are effective agents in several types of can-
cer, and docetaxel is the standard taxane. In a randomized 
phase II trial, elderly metastatic breast cancer patients who 
took docetaxel presented a higher incidence of stomatitis, 
neutropenia, and neurotoxicity (Biganzoli et al., 2009).
Antiulcer drugs
In general, proton pump inhibitors are considered 
safe and effective drugs in the elderly (Zarowitz, 2009). 
However, patients who took them for more than 1 year 
were found to be at increased risk for hip fractures, and 
it was observed that this effect is dose-related (Yang et 
al., 2006). It is possible that this is due to reduced cal-
cium absorption. Dosage adjustment of the proton pump 
inhibitors in patients with renal impairment is not neces-
sary, but in patients with hepatic impairment the dosage 
of pantoprazole and rabeprazole should be decreased 
(Zarowitz, 2009).
Cimetidine is associated with more clinically impor-
tant drug interactions than the other histamine-2 antago-
nists and this medicine can cause several adverse effects, 
such as bradycardia, arrhythmias, confusion, depression, 
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thrombocytopenia, neutropenia, and gynecomastia. For 
these reasons, cimetidine is not recommended for use in 
older people. Famotidine and ranitidine can cause impo-
tence, and ranitidine may contribute to cognitive decline, 
because of their significant anticholinergic properties. 
Therefore, famotidine and other proton pump inhibitors 
that present less anticholinergic properties than ranitidine, 
are preferable in order to avoid these effects in elderly 
patients (Zarowitz, 2009).
FINAL CONSIDERATIONS
The pharmacologic treatment of diseases in elderly 
patients is a great challenge for manifold reasons. Firstly, 
age influences drug absorption due to various factors such 
as rise in gastric pH, reduction in gastrointestinal motility 
and reduction in splanchnic blood flow. Secondly, reduced 
lean body mass and increased body fat result in higher 
concentrations of drugs such as lithium that are distri-
buted in the body fluids, increasing the distribution and 
prolonging the half-life elimination of fat-soluble drugs, 
such as benzodiazepines. Thirdly, the metabolite clearance 
of hepatic and renal eliminated drugs may decrease with 
age, resulting in slower drug clearance. Lastly, the pre-
sence of medical illness and increase in age may result in 
pharmacodynamic changes. Finally, there are many drugs 
that are contraindicated for the elderly, and therefore much 
caution is required to treat them. All health professionals 
should be aware of the changes occurring in elderly indi-
viduals, and those prescribing drugs should always take 
the changes occurring in drug pharmacokinetics and phar-
macodynamics during aging into consideration, in order 
to avoid compromising the health of the elderly through 
inappropriate prescriptions.
 Pharmacists are also important professionals who 
play a key role in avoiding this problem. The medicines 
should always be dispensed by a pharmacist, who can give 
orientation to the patient and identify possible contrain-
dications for the elderly, considering the particularities 
and needs of each individual. Through this approach, 
pharmacists can contribute toward more rational use of 
drugs by elderly patients.
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